Physician profile
Candyce Lucian
NPI 1871596429
$3,201.05
in general payments reported to CMS, 2019-2025
20 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $961 · 2020: $238 · 2021: $248 · 2022: $379 · 2023: $511 · 2024: $581 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,375.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $863.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $497.58 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $241.64 | 2019-2025 | |
| Astellas Pharma US INC | $238.96 | 2019-2025 | Veozah |
| Pfizer INC. | $202.18 | 2019-2025 | |
| Exact Sciences Corporation | $197.39 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $183.10 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $148.46 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $128.84 | 2019-2020 | |
| Amgen INC. | $110.70 | 2019-2021 | |
| Mylan Specialty L.P. | $77.85 | 2024 | Yupelri |
| Amarin Pharma, INC. | $71.93 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $53.03 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.27 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $47.33 | 2024-2025 | Voquezna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $23.75 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $20.55 | 2020 | |
| Dexcom, INC. | $17.67 | 2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $13.29 | 2024 | Shingrix, Arexvy |
| Nalpropion Pharmaceuticals LLC | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candyce Lucian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.